Compare · BDX vs CARL
BDX vs CARL
Side-by-side comparison of Becton Dickinson and Company (BDX) and Carlsmed Inc. (CARL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and CARL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 138.6x CARL ($380.9M).
- Over the past year, BDX is up 0.3% and CARL is down 6.0% - BDX leads by 6.3 points.
- CARL has been more active in the news (12 items in the past 4 weeks vs 8 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 6 for CARL).
- Company
- Becton Dickinson and Company
- Carlsmed Inc.
- Price
- $191.68-1.09%
- $13.44-4.21%
- Market cap
- $52.78B
- $380.9M
- 1M return
- +5.72%
- -12.50%
- 1Y return
- +0.32%
- -6.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 6
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest CARL
- SEC Form 144 filed by Carlsmed Inc.
- Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
- SEC Form 4 filed by Carlsmed Inc.
- Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Operating Officer Bertolini Jeffrey sold $3,400 worth of shares (243 units at $13.99) as part of a pre-agreed trading plan and exercised 243 shares at a strike of $2.23 (SEC Form 4)
- SEC Form S-8 filed by Carlsmed Inc.
- Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
- New insider Kamocsay Jennifer claimed ownership of 56,222 shares (SEC Form 3)
- CFO, Treasurer Heppenstall Richard was granted 89,286 shares (SEC Form 4)
- SEC Form 3 filed by new insider Heppenstall Richard